삼성서울병원

Ko En
의료진 검색
찾으실 의료진명을 입력하여 검색해주세요.

혈액종양내과 이세훈 교수

진료분야
폐암, 식도암, 두경부암, 뇌종양
진료일정 05 月
날짜
수
01
목
02
금
03
토
04
일
05
월
06
화
07
수
08
목
09
금
10
토
11
일
12
월
13
화
14
수
15
목
16
금
17
토
18
일
19
월
20
화
21
수
22
목
23
금
24
토
25
일
26
월
27
화
28
수
29
목
30
금
31
오전
오후
진료일정 06 月
날짜
토
01
일
02
월
03
화
04
수
05
목
06
금
07
토
08
일
09
월
10
화
11
수
12
목
13
금
14
토
15
일
16
월
17
화
18
수
19
목
20
금
21
토
22
일
23
월
24
화
25
수
26
목
27
금
28
토
29
일
30
오전
오후
본원외래 본원클리닉 본원육아상담 암병원외래 암병원클리닉 암병원육아상담

학력

학력
2008.02 서울대학교/의학과/박사
2001.02 서울대학교/의학과/석사
1996.02 서울대학교/의학과/학사

경력

경력
2015.03 ~현재 삼성서울병원, 성균관대학교 의과대학/교수
2005.04 ~ 2015.02 서울대학교병원, 서울대학교 의과대학/조교수, 부교수
2009.07 ~ 2011.01 Dana-Farber Cancer Institute, Boston (Harvard Medical school, Broad Institute)
2004.04 ~ 2005.03 삼성서울병원/전임강사
2002.03 ~ 2004.04 삼성서울병원/전임의
2001.05 ~ 2002.02 서울대학교병원/전임의

학회활동

학회활동
2013.01 ~ 현재 대한유전체학회/2014동계학술위원(역임), 2015동계기획위원
2012.01 ~ 현재 생화학분자생물학회(KSBMB)/2013정기학술위원(역임)
2011.01 ~ 현재 신경종양학회(SNO)/회원
2011.01 ~ 현재 대한신경종양학회/보험및대외협력위원장(역임), PRC위원, 다학제위원회 등록책임위원
2010.01 ~ 현재 대한두경부종양학회/편집위원(역임)
2008.01 ~ 현재 국제폐암학회(IASLC)/회원
2007.01 ~ 현재 미국암연구학회(AACR)/회원
2007.01 ~ 현재 대한폐암학회/학술위원(역임), 기획위원(역임)
2005.01 ~ 현재 한국임상암학회/교육위원(역임), 편집위원(역임), 학술위원, 기획위원
2003.01 ~ 현재 미국임상암학회(ASCO)/회원
2001.01 ~ 현재 대한암학회/회원,대한암학회산하항암요법연구회/폐암분과위원(역임), 두경부암분과위원, 비뇨기암분과위원, PRC위원
2001.01 ~ 현재 대한내과학회/혈액종양내과분과위원(역임)
논문
  • BMC Cancer. 2017 May 15;17(1):330. doi: 10.1186/s12885-017-3282-9. Characterization of genetic aberrations in a single case of metastatic thymic adenocarcinoma Lee Y11, Park S2, Lee SH3,4, Lee H5.
    View PubMed
  • Expert Opin Drug Saf. 2017 Apr;16(4):465-469. doi: 10.1080/14740338.2017.1300656. Epub 2017 Mar 8. EGFR TKI combination with immunotherapy in non-small cell lung cancer Ahn MJ11, Sun JM1, Lee SH1, Ahn JS1, Park K1.
    View PubMed
  • Ann Oncol. 2017 Mar 1;28(3):547-554. doi: 10.1093/annonc/mdw669. Rapamycin-insensitive companion of mTOR (RICTOR) amplification defines a subset of advanced gastric cancer and is sensitive to AZD2014-mediated mTORC1/2 inhibition Kim ST11, Kim SY1, Klempner SJ2,3, Yoon J4, Kim N4, Ahn S4,5, Bang H5,6, Kim KM5,6, Park W4, Park SH1, Park JO1, Park YS1, Lim HY1, Lee SH1, Park K1,6, Kang WK1, Lee J1.
    View PubMed
  • Lancet Respir Med. 2017 Feb;5(2):e10. doi: 10.1016/S2213-2600(17)30010-3. Two recent phase 2 trials of vandetanib in RET-rearranged NSCLC Lee SH11, Lee JK2.
    View PubMed
  • Expert Opin Pharmacother. 2017 Feb;18(2):225-231. doi: 10.1080/14656566.2017.1285283. Osimertinib for the treatment of non-small cell lung cancer Sun JM11, Lee SH1, Ahn JS1, Park K1, Ahn MJ1.
    View PubMed
  • Ann Oncol. 2017 Feb 1;28(2):292-297. doi: 10.1093/annonc/mdw559. Vandetanib in pretreated patients with advanced non-small cell lung cancer-harboring RET rearrangement: a phase II clinical trial Lee SH11, Lee JK2, Ahn MJ1, Kim DW2, Sun JM1, Keam B2, Kim TM2, Heo DS2, Ahn JS1, Choi YL3, Min HS4, Jeon YK4, Park K1.
    View PubMed
  • RADIOTHERAPY AND ONCOLOGY, FEB 2017, 122(2):217-223, DOI: 10.1016/j.radonc.2016.09.015 A phase II trial of concurrent chemoradiotherapy with weekly docetaxel plus cisplatin treatment for unresectable locally advanced head and neck cancer Lee JY1, Sun JM, Oh D, Lim SH, Chi S, Lee SH, Jung SH, Ahn MJ, Ahn YC, Park K
    View PubMed
  • Cancer Res Treat. 2017 Jan;49(1):193-203. doi: 10.4143/crt.2015.473. Epub 2016 Jun 27. Concurrent Chemoradiotherapy with Temozolomide Followed by Adjuvant Temozolomide for Newly Diagnosed Glioblastoma Patients: A Retrospective Multicenter Observation Study in Korea Kim BS11, Seol HJ2, Nam DH2, Park CK3, Kim IH4, Kim TM5, Kim JH6, Cho YH6, Yoon SM7, Chang JH8, Kang SG8, Kim EH8, Suh CO9, Jung TY10, Lee KH11, Kim CY12, Kim IA13, Hong CK14, Yoo H15, Kim JH16, Kang SH17, Kang MK18, Kim EY19, Kim SH20, Chung DS21, Hwang SC22, Song JH23, Cho SJ24, Lee SI25, Lee YS26, Ahn KJ27, Kim SH28, Lim DH29, Gwak HS30, Lee SH31, Hong YK32.
    View PubMed
  • Cancer Res Treat. 2017 Jan;49(1):129-140. doi: 10.4143/crt.2015.466. Epub 2016 May 18. Post-bevacizumab Clinical Outcomes and the Impact of Early Discontinuation of Bevacizumab in Patients with Recurrent Malignant Glioma Cha Y11, Kim YJ2, Lee SH1,3, Kim TM1, Choi SH4, Kim DW1, Park CK5, Kim IH6, Kim JH2, Kim E7, Choi B7, Kim CY8, Kim IA9, Heo DS1.
    View PubMed
  • Oncotarget. 2017 Jan 10;8(2):3237-3245. doi: 10.18632/oncotarget.13700. The implication of FLT3 amplification for FLT targeted therapeutics in solid tumors Lim SH11, Kim SY1, Kim K2, Jang H1, Ahn S2, Kim KM2, Kim NK3, Park W3, Lee SJ1, Kim ST1, Park SH1, Park JO1, Park YS1, Lee SH1, Lim HY1, Park K1, Kang WK1, Lee J1.
    View PubMed
  • JOURNAL OF SURGICAL ONCOLOGY, DEC 1 2016, 114(7):888-894, DOI: 10.1002/jso.24412 Prognostic significance of clinical and F-18-FDG PET/CT parameters for post-distant metastasis survival in head and neck squamous cell carcinoma patients Cho JK1, Hyun SH, Choi JY, Choi N, Kim MJ, Lee SH, Baek KH, Jeong HS
    View PubMed
  • J Thorac Oncol. 2016 Dec;11(12):2051-2052. doi: 10.1016/j.jtho.2016.09.130. Transient Asymptomatic Pulmonary Opacities during Osimertinib Treatment: "Stop or Go" Decision Ahn MJ11, Sun JM2, Lee SH2, Ahn JS2, Park K2.
    View PubMed
  • Cancer. 2016 Oct;122(19):3024-31. doi: 10.1002/cncr.30135. Epub 2016 Jun 17. Efficacy and Safety of Dovitinib in Pretreated Patients With Advanced Squamous Non-Small Cell Lung Cancer With FGFR1 Amplification: A Single-Arm, Phase 2 Study Lim SH11, Sun JM1, Choi YL2, Kim HR3, Ahn S2, Lee JY1, Lee SH1, Ahn JS1, Park K1, Kim JH3, Cho BC4, Ahn MJ5.
    View PubMed
  • Invest New Drugs. 2016 Aug;34(4):407-15. doi: 10.1007/s10637-016-0350-y. Epub 2016 Apr 5. AZD9291 overcomes T790 M-mediated resistance through degradation of EGFR(L858R/T790M) in non-small cell lung cancer cells Ku BM11, Bae YH1, Koh J1, Sun JM2, Lee SH2, Ahn JS2, Park K2, Ahn MJ3,4.
    View PubMed
  • Med Oncol. 2016 Aug;33(8):97. doi: 10.1007/s12032-016-0811-3. Epub 2016 Jul 22. Analysis of the benefit of sequential cranial radiotherapy in patients with EGFR mutant non-small cell lung cancer and brain metastasis Byeon S11, Ham JS1, Sun JM2, Lee SH2, Ahn JS2, Park K2, Ahn MJ3.
    View PubMed
  • Lung Cancer. 2016 Jun;96:48-51. doi: 10.1016/j.lungcan.2016.03.012. Epub 2016 Mar 26. Assessment of objective responses in thymic epithelial tumors using ITMIG modified criteria Kim HS11, Lee JY2, Lim SH2, Sun JM2, Lee SH2, Ahn JS2, Park K2, Ahn MJ3.
    View PubMed
  • Clin Cancer Res. 2016 May 1;22(9):2139-45. doi: 10.1158/1078-0432.CCR-15-1653. Epub 2015 Dec 14. A Phase Ib/II Study of Afatinib in Combination with Nimotuzumab in Non-Small Cell Lung Cancer Patients with Acquired Resistance to Gefitinib or Erlotinib Lee JY11, Sun JM1, Lim SH1, Kim HS, Yoo KH1, Jung KS1, Song HN1, Ku BM2, Koh J2, Bae YH2, Lee SH1, Ahn JS1, Park K1, Ahn MJ3.
    View PubMed
  • Cancer Res Treat. 2016 Apr;48(2):527-36. doi: 10.4143/crt.2015.249. Epub 2015 Sep 15. Association between PD-L1 and HPV Status and the Prognostic Value of PD-L1 in Oropharyngeal Squamous Cell Carcinoma Kim HS11, Lee JY1, Lim SH1, Park K1, Sun JM1, Ko YH2, Baek CH3, Son YI3, Jeong HS3, Ahn YC4, Lee MY5, Hong M6, Ahn MJ1.
    View PubMed
  • Oncotarget. 2016 Apr 26;7(17):23874-84. doi: 10.18632/oncotarget.8074. Clinicopathologic characteristics of EGFR, KRAS, and ALK alterations in 6,595 lung cancers Lee B11,2, Lee T1, Lee SH3,2, Choi YL1,2, Han J1.
    View PubMed
  • Cancer Biomark. 2016;16(3):425-33. doi: 10.3233/CBM-160581. Pretreatment albumin-to-globulin ratio as a predictive marker for tyrosine kinase inhibitor in non-small cell lung cancer Park S11, Park S1, Lee SH1,2, Suh B3, Ock CY1, Keam B1, Kim TM1, Kim DW1, Kim YW1, Heo DS1.
    View PubMed
  • EXPERT OPINION ON BIOLOGICAL THERAPY, MAR 3 2016, 16(3):397-406 , DOI: 10.1517/14712598.2016.1145652 Pembrolizumab for the treatment of non-small cell lung cancer Lim SH1, Sun JM, Lee SH, Ahn JS, Park K, Ahn MJ
    View PubMed
  • Thyroid. 2016 Mar;26(3):404-13. doi: 10.1089/thy.2015.0316. Epub 2015 Dec 14. Changes of Clinicopathologic Characteristics and Survival Outcomes of Anaplastic and Poorly Differentiated Thyroid Carcinoma Lee DY11, Won JK2, Lee SH3, Park do J4, Jung KC2, Sung MW5, Wu HG6, Kim KH5, Park YJ4, Hah JH5.
    View PubMed
  • Oncotarget. 2016 Mar 22;7(12):14803-13. doi: 10.18632/oncotarget.7543. The CDK4/6 inhibitor LY2835219 has potent activity in combination with mTOR inhibitor in head and neck squamous cell carcinoma Ku BM11, Yi SY2, Koh J1, Bae YH1, Sun JM3, Lee SH3, Ahn JS3, Park K3, Ahn MJ3.
    View PubMed
  • BMC Cancer. 2016 Feb 29;16:170. doi: 10.1186/s12885-016-2209-1. Clinical application of genomic profiling to find druggable targets for adolescent and young adult (AYA) cancer patients with metastasis Cha S11, Lee J2, Shin JY3, Kim JY4, Sim SH5, Keam B6,7, Kim TM8,9, Kim DW10,11, Heo DS12,13, Lee SH14,15,16,17, Kim JI18,19,20,21.
    View PubMed
  • Radiother Oncol. 2016 Feb;118(2):244-50. doi: 10.1016/j.radonc.2015.11.030. Epub 2015 Dec 17. Comparison of weekly versus triweekly cisplatin delivered concurrently with radiation therapy in patients with locally advanced nasopharyngeal cancer: A multicenter randomized phase II trial (KCSG-HN10-02) Lee JY11, Sun JM1, Oh DR2, Lim SH1, Goo J3, Lee SH1, Kim SB4, Park KU5, Kim HK6, Hong DS7, Kim JS8, Kim SG9, Yi SY10, Yun HJ11, Hyun MS12, Kim HJ13, Jung SH3, Park K1, Ahn YC14, Ahn MJ15.
    View PubMed
  • Oncotarget. 2016 Feb 9;7(6):6984-93. doi: 10.18632/oncotarget.6874. Longitudinal monitoring of EGFR mutations in plasma predicts outcomes of NSCLC patients treated with EGFR TKIs: Korean Lung Cancer Consortium (KLCC-12-02) Lee JY11, Qing X2, Xiumin W2, Yali B2, Chi S3, Bak SH4, Lee HY5, Sun JM1, Lee SH1, Ahn JS1, Cho EK6, Kim DW7, Kim HR8, Min YJ9, Jung SH3, Park K1, Mao M2, Ahn MJ1.
    View PubMed
  • J Thorac Oncol. 2015 Dec;10(12):1667-9. doi: 10.1097/JTO.0000000000000701. The MISSION Impossible No, the Journey Should Continue with Better Targeting! Lee SH11, Park K.
    View PubMed
  • Oncotarget. 2015 Dec 22;6(41):43653-66. doi: 10.18632/oncotarget.6189. Genomic dynamics associated with malignant transformation in IDH1 mutated gliomas Park CK11, Park I2, Lee S3, Sun CH3, Koh Y4, Park SH5, Kim JE1, Yun H3, Lee SH6.
    View PubMed
  • J Thorac Oncol. 2015 Dec;10(12):1800-6. doi: 10.1097/JTO.0000000000000692. A Prospective Phase II Study of Cisplatin and Cremophor EL-Free Paclitaxel (Genexol-PM) in Patients with Unresectable Thymic Epithelial Tumors Kim HS11, Lee JY, Lim SH, Sun JM, Lee SH, Ahn JS, Park K, Moon SH, Ahn MJ.
    View PubMed
  • Lung Cancer. 2015 Nov;90(2):261-6. doi: 10.1016/j.lungcan.2015.08.020. Epub 2015 Sep 4. Pemetrexed plus platinum versus pemetrexed alone in non-small cell lung cancer patients who have progressed after first-line EGFR TKIs Lee SJ11, Sun JM1, Lee SH1, Ahn JS1, Park K1, Ahn MJ2.
    View PubMed
  • J Neurooncol. 2015 Aug;124(1):101-10. doi: 10.1007/s11060-015-1808-z. Epub 2015 May 31. Prognostic implication of progression pattern after anti-VEGF bevacizumab treatment for recurrent malignant gliomas Kim BS11, Kim SK, Choi SH, Lee SH, Seol HJ, Nam DH, Lee JI, Park CK, Kong DS.
    View PubMed
  • Oncotarget. 2015 Aug 21;6(24):20266-77. Mechanism for enhanced 5-aminolevulinic acid fluorescence in isocitrate dehydrogenase 1 mutant malignant gliomas Kim JE11, Cho HR2, Xu WJ3, Kim JY1, Kim SK4, Kim SK1,5, Park SH6, Kim H2, Lee SH7, Choi SH2, Park S3, Park CK1.
    View PubMed
  • PLoS One. 2015 Jul 22;10(7):e0133371. doi: 10.1371/journal.pone.0133371. eCollection 2015. Predictive and Prognostic Value of Ribonucleotide Reductase Regulatory Subunit M1 and Excision Repair Cross-Complementation Group 1 in Advanced Urothelial Carcinoma (UC) Treated with First-Line Gemcitabine Plus Platinum Combination Chemotherapy Kim M11, Ku JH2, Kwak C2, Kim HH2, Lee E2, Keam B3, Kim TM3, Heo DS3, Lee SH4, Moon KC5.
    View PubMed
  • Cancer Chemother Pharmacol. 2006 Jan;57(1):91-6. Epub 2005 Nov 5. Anemia is the strongest prognostic factor for outcomes of 5-fluorouracil-based first-line chemotherapy in patients with advanced gastric cancer Park SH11, Lee J, Lee SH, Park JO, Kim K, Kim WS, Jung CW, Park YS, Kang WK, Park K, Kim S, Bang SM, Cho EK, Shin DB, Lee JH.
    View PubMed
  • J Cell Biochem. 2005 Mar 1;94(4):695-707. Arsenic trioxide represses constitutive activation of NF-kappa B and COX-2 expression in human acute myeloid leukemia, HL-60 Han SS11, Kim K, Hahm ER, Park CH, Kimler BF, Lee SJ, Lee SH, Kim WS, Jung CW, Park K, Kim J, Yoon SS, Lee JH, Park S.
    View PubMed
  • Biol Blood Marrow Transplant. 2005 Feb;11(2):122-8. Infused CD34+ cell dose predicts long-term survival in acute myelogenous leukemia patients who received allogeneic bone marrow transplantation from matched sibling donors in first complete remission Lee SH11, Lee MH, Lee JH, Min YH, Lee KH, Cheong JW, Lee J, Park KW, Kang JH, Kim K, Kim WS, Jung CW, Choi SJ, Lee JH, Park K.
    View PubMed
  • Cell Signal. 2005 Jan;17(1):111-9. Activation of Rafl and the ERK pathway in response to L-ascorbic acid in acute myeloid leukemia cells Park S11, Park CH, Hahm ER, Kim K, Kimler BF, Lee SJ, Park HK, Lee SH, Kim WS, Jung CW, Park K, Riordan HD, Lee JH.
    View PubMed
  • Bone Marrow Transplant. 2003 Nov;32(9):889-95. Autologous peripheral blood stem cell transplantation with induction of autologous graft-versus-host disease in acute myeloid leukemia Park J11, Lee MH, Lee HR, Park SH, Lee SH, Lee KE, Lee H, Park JO, Kim K, Jung CW, Im YH, Kang WK, Ko YH, Park K.
    View PubMed